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Abstract
Introduction The molecular mechanisms underlying cartilage
destruction in osteoarthritis are poorly understood. Proteolysis
is a key feature in the turnover and degradation of cartilage
extracellular matrix where the focus of research has been on the
metzincin family of metalloproteinases. However, there is strong
evidence to indicate important roles for other catalytic classes of
proteases, with both extracellular and intracellular activities. The
aim of this study was to profile the expression of the majority of
protease genes in all catalytic classes in normal human cartilage
and that from patients with osteoarthritis (OA) using a
quantitative method.
Methods Human cartilage was obtained from femoral heads at
joint replacement for either osteoarthritis or following fracture to
the neck of femur (NOF). Total RNA was purified, and
expression of genes assayed using Taqman® low-density array
quantitative RT-PCR.
Results A total of 538 protease genes were profiled, of which
431 were expressed in cartilage. A total of 179 genes were
differentially expressed in OA versus NOF cartilage: eight
aspartic proteases, 44 cysteine proteases, 76
metalloproteases, 46 serine proteases and five threonine
proteases. Wilcoxon ranking as well as the LogitBoost-NR
machine learning approach were used to assign significance to
each gene, with the most highly ranked genes broadly similar
using each method.
Conclusions This study is the most complete quantitative
analysis of protease gene expression in cartilage to date. The
data help give direction to future research on the specific
function(s) of individual proteases or protease families in
cartilage and may help to refine anti-proteolytic strategies in OA.
Introduction
Osteoarthritis (OA) is a debilitating degenerative joint disease
where degradation of articular cartilage is a key feature [1].
Given the current demographic trend toward an older popula-
tion, OA – for which age is an important risk factor – will be an
increasing health and economic burden on society.
The molecular mechanisms underlying cartilage destruction in
OA are poorly understood (see for example [1]). Cartilage is
made up of two main extracellular matrix macromolecules: type
II collagen and aggrecan, a large aggregating proteoglycan.
The former endows the cartilage with its tensile strength,
whilst the latter enables cartilage to resist compression. Quan-
titatively more minor components (for example, type IX, type XI
and type VI collagens, biglycan, decorin, cartilage oligomeric
matrix protein) also have important roles in controlling the
supramolecular organization of the matrix. Normal cartilage
extracellular matrix is in a state of dynamic equilibrium, with a
balance between synthesis and degradation. For the degrada-
tive process there is a balance between proteases that
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degrade the extracellular matrix and their inhibitors. In OA, the
dogma is that a disruption of this balance, in favour of proteol-
ysis, leads to pathological cartilage destruction [2].
Cartilage destruction in OA is thought to be mediated by two
main enzyme families; the matrix metalloproteinases (MMPs)
are thought to be responsible for cartilage collagen break-
down, whilst enzymes from the ADAMTS (a disintegrin and
metalloproteinase domain with thrombospondin motifs) family
are thought to mediate cartilage aggrecan loss [3]. Whilst
there is strong evidence to support this tenet, there is also evi-
dence that indicates a role for enzymes in other catalytic
classes. Examples include serine proteases, which could
directly degrade the extracellular matrix or could be involved in
potentially rate-limiting activation of proMMPs [4]; similarly,
cathepsin K, capable of degrading the collagen triple helix, has
also been implicated in cartilage degradation (see for example
[5]).
With the completion of the sequencing of several mammalian
genomes, the full complement of protease genes has been
elucidated [6]. There are 570 human protease genes (not
including pseudogenes): 21 aspartate proteases, 154
cysteine proteases, 191 metalloproteases, 176 serine pro-
teases and 28 threonine proteases.
The present study therefore aimed to profile as many of these
genes as possible in human cartilage using a quantitative and
sensitive RT-PCR approach, and to compare normal tissue
with that from patients with OA.
Materials and methods
Collection of human cartilage and RNA purification
Human articular cartilage was obtained from femoral heads of
patients undergoing total-hip-replacement surgery at the Nor-
folk and Norwich University Hospital (Norwich, UK). Samples
from patients with OA (n = 12, six female patients and six male
patients; age range, 37 to 86 years; median age, 72 years;
mean age ± standard error of the mean, 68.8 ± 4.2 years)
were compared with cartilage from patients undergoing hip
replacement following fracture to the neck of femur (NOF) (n
= 12, six female patients and six male patients; age range, 68
to 94 years; median age, 84 years; mean age ± standard error
of the mean, 81.8 ± 2.4 years). OA was diagnosed using the
clinical history and an examination of the patient, coupled with
X-ray findings; confirmation of gross pathology was made at
the time of joint removal. The fracture patients had no known
history of joint disease and their cartilage was free of lesions;
80% of these patients underwent surgery within 36 hours of
fracture. This study was performed with Ethical Committee
approval, and all patients provided informed consent.
Intact femoral heads were washed in sterile PBS. Cartilage
samples were removed from the femoral head using a razor
blade, chopped into pieces of 2 to 5 mm, and were snap-fro-
zen in liquid nitrogen within 15 to 30 minutes of surgery. The
cartilage was weighed and ground under liquid nitrogen using
the Type 6750 Freezer Mill (Spex Certiprep, Glen Creston,
Stanmore, UK). RNA was purified essentially following David-
son and colleagues [7]. TRIzol® reagent (Invitrogen Life Tech-
nologies, Paisley, UK) was added to ground cartilage (1 ml/0.2
g cartilage), mixed thoroughly and incubated at room temper-
ature for 5 minutes. Ground cartilage was pelleted at 9,500 ×
g for 10 minutes at 4°C, and the supernatant was recovered.
Then 300 μl chloroform was added per 0.5 ml TRIzol®, vor-
texed for 15 seconds and incubated at room temperature for
10 minutes. TRIzol®/chloroform solution was centrifuged at
9,500 × g for 15 minutes at 4°C, and the aqueous layer was
recovered into a fresh tube. Then 0.5× volume, 100% ethanol
was added and mixed. Using the RNeasy Mini Kit (Qiagen,
Crawley, UK), samples were applied to spin columns and cen-
trifuged at 9,500 × g for 15 seconds, and the flow-through
was discarded. Columns were then washed and eluted
according to the manufacturer's instructions. RNA samples
were quantified using the NanoDrop®  spectrophotometer
(NanoDrop Technologies, Wilmington, Delaware, USA) and
were stored at -80°C. cDNA was synthesized from 2 μg total
RNA using Superscript II reverse transcriptase (Invitrogen)
and random hexamers according to the manufacturer's
instructions. cDNA was stored at -20°C.
Quantitative RT-PCR and Taqman® low-density arrays
Quantitative RT-PCR was performed as previously described
[7]. Prior to low-density array analysis, samples were assayed
for 18S rRNA to ensure that all samples were within 1.5
threshold cycle (Ct) of the median value as a baseline quality
control. Samples were also assayed for genes previously
shown to be differentially expressed in OA cartilage compared
with NOF (MMP28 and ADAMTS16).
Custom-designed microfluidic Taqman®  low-density arrays
were obtained from Applied Biosystems (Warrington, UK) with
primer sets designed to amplify with similar efficiencies, allow-
ing comparison between genes. The arrays contained 538
protease assays across two microfluidic cards along with 12
housekeeping genes on each card. The Taqman® low-density
arrays were used according to the manufacturer's protocol.
Briefly, 800 ng cDNA was added to 2× TaqMan® Master Mix
(Applied Biosystems) and was loaded onto each card by cen-
trifugation. Relative quantification of genes on the cards was
performed using the ABI Prism® 7900 HT (Applied Biosys-
tems, Warrington, UK) sequence detection system under the
following cycling conditions: 50°C for 2 minutes, 94.5°C for
10 minutes, then 40 cycles of 97°C for 30 seconds, and
59.7°C for 1 minute. The data were analysed using Statminer
software (Integromics, Philadelphia, Pennsylvania, USA). The
geNorm facility within Statminer identified succinate dehydro-
genase subunit A as the most stable housekeeping gene, and
the data were therefore normalized to succinate dehydroge-
nase subunit A expression.Available online http://arthritis-research.com/content/11/3/R96
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Statistical analyses
Statistical analysis was by Mann – Whitney U test (either
SPSS 16.0, SPSS, Woking, UK, or GraphPad Prism 4,
GraphPad Software, La Jolla, USA) or using the LogitBoost-
NR algorithm as described below.
Machine learning approach for analysing gene expression 
data
Machine learning methods were applied to the analysis of
gene expression data because of their high dimensionality and
complexity: in this case, 538 genes and 24 samples.
LogitBoost-NR ensemble for classification of samples
A machine learning ensemble can be simply viewed as a com-
bination of a number of models that have been trained inde-
pendently from the available data of a given problem and then
work collectively in order to produce better solutions. The prin-
ciple behind ensemble learning is that although a classification
algorithm may only be able to produce a model with slightly
better accuracy than random guessing, if several such models
are produced and combined into an ensemble, their combined
accuracy will be greater than any single classifier, providing
they are sufficiently diverse from each other to avoid making
similar errors, and boosting algorithms are designed with the
aim of producing a high level of diversity.
Ensemble classification methods such as boosting have been
applied to the classification of gene expression data and have
produced more accurate results [8] than the individual models
that work alone. Boosting algorithms such as LogitBoost [9]
iteratively employ another classification algorithm known as
the base learner to learn from the data samples and generate
a series of models. In the case of gene expression data, the
most common base learner used is the decision tree or deci-
sion stump, which is a decision tree consisting of a single
node. Initially all samples are assigned equal weights for train-
ing the first model or classifier. Then the accuracy of the pro-
duced model is measured and the weights of individual
samples are adjusted so that the weights of misclassified sam-
ples are increased (that is, boosted) while those of correctly
classified samples are reduced. At the next iteration the base
learner will concentrate on learning the information repre-
sented by the misclassified samples. This boosting process
goes on until a preset stopping criterion (such as either all of
the samples have been learned correctly or a fixed number of
iterations) is met. After the boosting process a series of mod-
els is therefore produced with the sample weights being pos-
sibly adjusted at each iteration. These models are then
combined to form an ensemble of classifiers. The ensemble is
then validated and tested using different data samples before
being used for classifying new samples by combining the out-
puts of the models by simple majority or weighted voting.
The LogitBoost-NR algorithm [10] is an extension of Logit-
Boost [9] and was specifically designed for the classification
of gene expression data. This was achieved by incorporating
feature nonreplacement, where the data features (genes) used
to construct a model at a given round of boosting are not avail-
able at subsequent rounds. This ensures that the models con-
structed at different boosting rounds use different genes,
which helps to achieve a high diversity between the models in
the ensemble. Such an approach is particularly appropriate in
conditions such as OA where many genes may be significant
to the pathology of the disease. Boosting algorithms are also
able to produce accurate predictive ensembles when the
number of features (genes) in the data is much larger than the
number of samples, as is the usually the case with gene
expression data, whereas conventional techniques such as
logistic regression are unable to do this. More details of the
LogitBoost-NR methodology can be found in Additional data
file 1.
Boosting ensemble for gene selection/ranking
The particular genes used in a classification ensemble pro-
duced by boosting as described above can be reasonably
assumed to be the most important in the pathology of the dis-
ease in question, and a method for ranking genes based on
LogitBoost-NR is described in Guile and Wang [10]. In this
method a training dataset consisting of the data for two-thirds
of the samples is randomly partitioned from a complete data-
set. The LogitBoost-NR algorithm with decision stumps as
base learner is then applied for 25 iterations of boosting to
construct a classification ensemble using 25 different genes.
The process is repeated for 50 different random partitions of
the data and the genes are scored according to the frequency
of their presence in the ensembles generated. A gene used in
all 50 ensembles therefore receives a score of 50, while a
gene that is only used once receives a score of 1. The genes
are then ranked according to their scores.
This ranking method was found to be much more effective than
the Wilcoxon test for selecting the genes most useful for pre-
dictive classification of DNA microarray data [10]. We applied
this method to the gene expression data obtained for the
present study to obtain a ranking of the genes. We tested this
by performing predictive classification using the top-ranked
genes with LogitBoost-NR. Because of the small number of
samples available in the present study compared with the
microarray datasets originally used for developing the Logit-
Boost-NR classification and gene selection methods [8,10],
we used equal-sized training and testing datasets of the data
when making the train:test splits, rather than two-thirds:one-
third.
Results
At the time of assay design, the Taqman® low-density array for-
mat allowed us to assay 538 of the 570 human proteases
(94%; 21 aspartic proteases, 139 cysteine proteases, 188
metalloproteases, 162 serine proteases and 28 threonine pro-
teases). At the time of writing there are an additional 15 assaysArthritis Research & Therapy    Vol 11 No 3    Swingler et al.
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available in this format, so 553 genes could now be assayed
(97%). These 538 assays were split across two Taqman® low-
density array cards along with a number of controls (for exam-
ple, replicates, housekeeping genes, extracellular matrix
genes).
We used the median Ct of each gene (without normalization)
as an approximate measure of its expression, assigning 20 <
Ct < 25 as very high, 25 < Ct < 30 as high, 30 < Ct < 35 as
moderate, 35 < Ct < 40 as low, and Ct = 40 as not detected,
based on our previous experience [11]. Table 1 presents the
spread of gene expression in each of these bands and demon-
strates that the majority of genes are expressed at the moder-
ate to high level. Moreover, there is a general increase in gene
expression in the OA samples, with the largest change being
within the metalloproteases where several genes move from
the not detected or low bands up to the moderate band.
We included 12 frequently used housekeeping genes on each
Taqman® low-density array and used the geNorm algorithm to
select the most stable gene for normalization of the data [12].
Hence, all data were normalized to expression of succinate
dehydrogenase subunit A (a gene encoding a protein constit-
uent of the mitochondrial respiratory chain).
Table 2 presents the numbers of genes in each catalytic class
that are differentially expressed in OA and NOF with a signifi-
cance of P < 0.05 in a pairwise (OA vs. NOF) Mann – Whitney
U test. Figure 1 shows a box and whisker plot for the 26 genes
showing P < 0.0001 between these two groups.
Tables 3, 4, 5 and 6 show the fold change between the
median values of OA and NOF for all of the genes in each cat-
alytic class that are differentially expressed with a statistical
significance of P < 0.01 in the pairwise analysis. The median
Ct is included as an indication of expression level (as dis-
cussed above). Eight genes (IHH,  ADAM28,  ADAM33,
ASPA,  CRMP1,  MMP15,  MMP28  and  PCSK2) are not
expressed in NOF (that is, median Ct = 40) but are expressed
(35 > Ct > 32) in OA cartilage. Details of all genes analysed
can be found in Additional data file 2.
The simple analyses above demonstrate that assigning relative
importance to any gene in distinguishing OA from NOF is not
trivial. Unsupervised cluster analysis shows that the samples
are separated into OA and NOF based on their gene expres-
sion profiles (data not shown). Ranking the genes using the
Wilcoxon test yielded a relative order of importance in the abil-
ity of each gene to distinguish OA from NOF, but the rank
scores decrease relatively slowly across the genes such that
all genes are assigned at least some importance and the dif-
ference between the most and least important is small (Figure
2a). Similarly the top 15 genes are given identical rank and are
thus impossible to separate further. We therefore employed a
more sophisticated machine learning method originally devel-
oped for DNA microarray data analysis, based on the ensem-
ble learning algorithm LogitBoost-NR as described in [10], to
provide a second ranking of the genes. Figure 2b shows the
ranking scores, demonstrating an enhanced ability to assign
relative importance to each gene and also to exclude genes
with no contribution to separating the two groups, compared
with the standard methodology.
Table 7 presents the top 30 genes ranked by the LogitBoost-
NR algorithm with the Wilcoxon score for comparison. There
is broad similarity across the top genes ranked by both meth-
ods, although there is divergence – for example, heat shock 90
kDa protein 1 beta (HSP90AB1) is ranked equal top by Wil-
coxon but below the top 100 by LogitBoost-NR, and therefore
is not presented in the table. Full details of each ranking can
be found in Additional data file 3.
Discussion
The investigation of proteolysis in cartilage has been confined
to subsets of each catalytic class. Extracellular proteolysis par-
ticularly has been focused on the matrix-degrading metzincins
from the MMP and ADAMTS families. The aim of the present
study was to gain quantitative expression data for the majority
Table 1
Expression level of protease genes in each catalytic class
Expression level Aspartate proteases Cysteine proteases Metalloproteases Serine proteases Threonine proteases
NOF OA NOF OA NOF OA NOF OA NOF OA
20 < Ct < 25 0 1 2 4 2 4 3 3 0 0
25 < Ct < 30 10 10 85 80 70 74 47 51 16 17
30 < Ct < 35 4 5 33 38 52 70 29 33 8 6
35 < Ct < 40 2 1 8 6 17 5 19 21 1 2
ND 5 4 11 11 47 35 64 54 3 3
NOF, fracture to the neck of femur; OA, osteoarthritis; Ct, threshold cycle; ND, not detected (median Ct = 40).Available online http://arthritis-research.com/content/11/3/R96
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of proteases, both intracellular and extracellular, in all catalytic
classes.
Validation of the Taqman® low-density array data in this study
can be achieved in part by comparison with our previously
published data for the MMP and ADAMTS families in similar
tissue cohorts. Of the 27 genes in these families shown to be
differentially expressed in NOF compared with OA in the
present study, 25 genes were regulated similarly in an earlier
cohort [7]. For MMP14  (P  = 0.03) and ADAMTS6  (P  =
0.007), we had not previously reported significant differences
between NOF and OA. Similarly, six genes shown to be differ-
entially expressed in the earlier cohort [7] were not identified
as such in the current study. Of these, MMP8,  MMP10,
ADAMTS3 and ADAMTS10 all exhibited the same increase or
decrease in expression between the NOF and OA, but this did
not reach statistical significance. MMP12 and ADAMTS20
were not detected in the current study and were detected only
at low levels in the earlier cohort [7]. These differences proba-
bly reflect variation between cohorts, variation in assay meth-
odology or primer sets used, inaccuracy in the assay itself
where expression levels are very low and/or problems of mul-
tiple testing. No correction for multiple testing has been
applied in our analyses of the data since this can often lead to
a type two error (false negatives). This would limit the utility of
gene expression studies where the validity of any multiple test-
ing procedure has yet to be ascertained [13].
We used two methods to assign significance to the genes
assayed, a standard Wilcoxon/Mann – Whitney U-test method
and the LogitBoost-NR methodology. The genes identified as
being most significant by the two different methods were
broadly similar, increasing confidence that these genes are the
most important. Whilst there are too many proteases to review
the potential role of each in OA individually, it is worth provid-
ing details of the most significantly regulated genes.
Table 2
Number of genes in each catalytic class showing differential expression between osteoarthritis and fracture groups
P < 0.05 P < 0.01 P < 0.001 P < 0.0001
Aspartic proteases 1 3 3 1
Cysteine proteases 17 15 6 6
Metalloproteases 19 25 23 9
Serine proteases 19 11 6 10
Threonine proteases 3 2 0 0
Numbers of genes showing statistical significance between the two groups (osteoarthritis versus fracture to the neck of femur (NOF)) in each 
catalytic class. Pairwise statistical analysis between groups was performed using the Mann-Whitney U test.
Figure 1
Genes showing most significant differential expression between osteoarthritis and fracture groups Genes showing most significant differential expression between osteoarthritis and fracture groups. Box and whisker plot for all genes displaying a 
statistical significance of P < 0.0001 by Mann-Whitney U test. For full gene names, see Tables 3 to 6. SDHA, succinate dehydrogenase subunit A; 
n.d., not detected.Arthritis Research & Therapy    Vol 11 No 3    Swingler et al.
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BACE1, the aspartic protease β-secretase, catalyses the rate-
limiting step in the production of amyloid beta, leading to
plaque formation in Alzheimer's disease [14]. A number of
substrates other than amyloid precursor protein have been
described for BACE1, although the focus has been on the
central nervous system. These include the shedding of the
ectodomain of IL-1 receptor type II – a decoy receptor that
acts as a ligand sink – from the cell surface, thereby limiting
the action of IL-1 [15]. Interestingly, in chondrocytes, insulin-
like growth factor (IGF)-1 has been shown to induce the level
of IL-1 receptor type II as a mechanism to counter the cata-
bolic effects of IL-1 [16]. An increase in BACE1 activity could
therefore potentiate IL-1 signalling, contributing to cartilage
destruction in OA.
A major class of ectodomain sheddases is the ADAM (a disin-
tegrin and metalloproteinase domain) family. ADAM12,
reported additionally to cleave some matrix components as
well as IGF binding proteins, has been linked to OA in genetic
association studies (for example [17]). ADAM8 is expressed
in the developing skeleton [18] and has been shown, along
with ADAM23, to be expressed during differentiation of mes-
enchymal stem cells into chondrocytes [19]. The most signifi-
cant difference in ADAM expression in OA compared with
normal is for ADAM22. This protein has no protease activity
and is presumed to have roles in cell adhesion or as a receptor
(with several binding proteins identified), particularly in the
nervous system since the ADAM22 null mouse displays ataxia
and peripheral nerve hypomyelination [20].
Following ectodomain shedding, some transmembrane pro-
teins undergo so-called regulated intramembrane proteolysis
[21], whereby the peptide bond is cleaved within the hydro-
phobic lipid bilayer, often releasing the cytoplasmic domain for
intracellular action. The best known of these intramembrane
cleaving proteases is γ-secretase, which cleaves amyloid pre-
cursor protein in the second step of amyloidogenesis. One
component of this enzyme is presenilin 2, also significantly
increased in expression in OA cartilage in this study. γ-Secre-
tase has recently been shown to process the IL-1 receptor
type I, the signalling receptor [22]. Other intramembrane
cleaving proteases come from the S2P (MBTPS1 and
MBTPS2), the signal peptide peptidases (or presenilin homo-
logues) and the rhomboids [23]. Many genes across these
families show significant changes in expression between nor-
mal and OA cartilage, and the potential to act in inflammatory
pathways – for example, SPPL2B (presenilin homolog 4) has
been shown to promote intramembrane proteolysis of TNFα
[24].
Two aspartic proteases significantly increased in expression in
OA are nuclear hormone interacting proteins (NRIP2  and
NRIP3). These proteases are recently discovered and have
not been reported in cartilage before, but nuclear hormone
receptors have many roles in cartilage homeostasis.
Cathepsin D is a lysosomal enzyme, capable of aggrecan
cleavage. Whilst a recent proteomics study confirms that
cathepsin D is highly expressed in chondrocytes [25], its role
in cartilage degradation remains equivocal.
Of the cysteine protease cathepsins, cathepsin K showed a
high level of expression in cartilage, as well as a robust and
significant increase in expression in OA. Cathepsin K is the
only vertebrate enzyme outside the MMP family capable of
degrading the collagen triple helix, but has also been shown to
degrade other matrix proteins. Cathepsin K activity has been
demonstrated in human articular cartilage and has been
shown to play a role in collagen cleavage in at least a subset
of OA patients [5].
Cathepsin O and cathepsin Z are also highly expressed genes
in cartilage and, again, significantly increased in expression in
OA tissue versus normal tissue. Little is known about the func-
tion of each of these enzymes, although they are presumed to
be active predominantly intracellularly [26,27]. Cathepsin H,
cathepsin C, cathepsin F, cathepsin W, cathepsin B and
cathepsin S are also increased in expression in OA tissue
Table 3
Fold change and threshold cycle for aspartate proteases showing significant difference between OA and NOF
Gene name Gene symbol P value Fold change OA/NOF Median threshold cycle
β-Secretase 1 BACE1 0.00005 2.9 30.7
Nuclear receptor interacting protein 2 NRIP2 0.00014 3.7 33.8
Presenilin homolog 4/SPPL2B SPPL2B 0.00028 1.9 28.1
Cathepsin D CTSD 0.00071 3.4 24.5
Presenilin 2 PSEN2 0.00137 1.9 30.1
Nuclear receptor interacting protein 3 NRIP3 0.00170 3.7 34.6
Pepsin A PGA3/4/5 0.00170 6.8 35.3
Fold change and median threshold cycle for all aspartate protease genes showing significant difference at P < 0.01 between osteoarthritis (OA) 
versus fracture to the neck of femur (NOF). P value from the Mann-Whitney U test.Available online http://arthritis-research.com/content/11/3/R96
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compared with normal tissue, with the converse being true for
cathepsin L.
The two classical calpains, calpain I (μ-calpain, the catalytic
subunit encoded by CAPN1) and cathepsin II (m-calpain, the
catalytic subunit encoded by CAPN2), are both highly
expressed in articular cartilage and significantly increased in
OA. This is also true for the related nonclassical calpains
encoded by CAPN5 and CAPN6. At least calpain II is capable
of cleaving aggrecan, with evidence for cleavage at the cal-
pain-sensitive site [28]. The expression of both calpain I and
cathepsin II can be induced by TNFα, whilst μ-calpain may
regulate TNFα induction of MMP3, at least in rheumatoid syn-
ovial cells [29].
Hypertrophic chondrocytes in the growth plate undergo pro-
grammed cell death, with recent evidence pointing to the proc-
ess of autophagy rather than (or as well as) classical
apoptosis. The same processes may occur during OA where
programmed cell death is also thought to occur [30]. Many
proteases are involved in these processes, caspases are
involved in classical apoptosis, autophagins are involved in the
formation of the autophagosome in autophagy, and lysosomal
cathepsins are involved in the degradation of proteins within
lysosomes [31]. Several of these proteases show regulation in
OA cartilage in the current study.
Related to these observations, mice deficient in the metallo-
protease Zmpste24 display a progeria syndrome similar to
Table 4
Fold change and threshold cycle for cysteine proteases showing significant difference between OA and NOF
Gene name Gene symbol P value Fold change OA/NOF Median threshold cycle
Cathepsin K CTSK 0.00005 5.2 26.0
Cathepsin Z CTSZ 0.00005 2.9 25.4
Calpain 2 CAPN2 0.00006 2.0 25.5
Calpain 1 CAPN1 0.00008 2.0 27.5
Calpain 6 CAPN6 0.00008 6.8 30.9
Cathepsin O CTSO 0.00008 2.4 28.2
Autophagin-2 AUTL2 0.00014 2.0 30.3
Cathepsin H CTSH 0.00022 3.9 30.1
γ-Glutamyl hydrolase GGH 0.00028 2.4 31.6
Cathepsin C CTSC 0.00071 3.4 28.7
Bleomycin hydrolase BLMH 0.00089 1.5 30.1
Ubiquitin-specific protease 19 USP19 0.00089 1.5 27.8
Ubiquitin-specific protease 18 USP18 0.00137 2.4 32.4
Cathepsin L CTSL 0.00170 0.40 24.8
Ubiquitin-specific protease 13 USP13 0.00256 0.61 28.2
Calpain 5 CAPN5 0.00464 2.3 31.4
Ubiquitin-specific protease 37 USP37 0.00464 0.46 30.1
Caspase-8 CASP8 0.00561 1.5 30.0
Cathepsin F CTSF 0.00561 1.8 25.7
Ubiquitin-specific protease 36 USP36 0.00561 0.56 29.3
Cathepsin W CTSW 0.00677 2.1 34.6
Ubiquitin C-terminal hydrolase 3 UCHL3 0.00677 1.2 30.3
Ubiquitin-specific protease 28 USP28 0.00813 0.58 29.1
Caspase-2 CASP2 0.00974 1.2 28.6
hGPI8 PIGK 0.00974 1.9 27.8
Sentrin/SUMO protease 2 SENP2 0.00974 0.56 27.4
Fold change and median threshold cycle for all cysteine protease genes showing significant difference at P < 0.01 between osteoarthritis (OA) 
versus fracture to the neck of femur (NOF). P value from the Mann-Whitney U test. SUMO, small ubiquitin-like modifier.Arthritis Research & Therapy    Vol 11 No 3    Swingler et al.
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Table 5
Fold change and threshold cycle for metalloproteases showing significant difference between OA and NOF
Gene name Gene symbol P value Fold change OA/NOF Median threshold cycle
ADAM22 ADAM22 0.00005 6.0 32.3
ADAMTS2 ADAMTS2 0.00005 8.1 29.1
Aminopeptidase-like 1 NPEPL1 0.00005 3.7 30.2
Stromelysin 1 MMP3 0.00005 0.03 22.5
Stromelysin 3 MMP11 0.00005 81.4 31.0
MMP23A/B MMP23A/B 0.00006 24.7 34.2
Mammalian tolloid-like 1 protein TLL1 0.00006 4.9 31.9
ADAMTS1 ADAMTS1 0.00008 0.37 26.3
Carboxypeptidase Z CPZ 0.00008 12.6 35.0
Procollagen C-proteinase BMP1 0.00011 2.9 29.2
MT3-MMP MMP16 0.00014 6.9 31.2
ADAMTS14 ADAMTS14 0.00017 11.2 33.5
ADAMTS16 ADAMTS16 0.00017 19.6 33.7
Aminopeptidase N ANPEP 0.00017 5.3 27.2
Dihydropyrimidinase-related protein 2 DPYSL2 0.00022 2.2 25.1
Pappalysin-2 PAPPA2 0.00022 0.28 30.4
Plasma Glu-carboxypeptidase PGCP 0.00022 2.9 29.9
Cytosol alanyl aminopeptidase NPEPPS 0.00028 0.69 25.7
Gelatinase A MMP2 0.00036 9.7 24.4
Leucyl aminopeptidase LAP3 0.00045 1.6 28.9
ADAMTS9 ADAMTS9 0.00057 0.10 30.4
Gelatinase B MMP9 0.00057 31.9 31.3
Aminopeptidase B-like 1 RNPEPL1 0.00071 2.1 29.5
Membrane dipeptidase 2 DPEP2 0.00071 5.6 35.1
NAALADASE II NAALAD2 0.00071 3.0 35.0
PM20D2 peptidase PM20D2 0.00071 0.36 27.6
ADAM12 ADAM12 0.00089 4.0 27.6
MMP19 MMP19 0.00089 16.5 29.8
MMP21 MMP21 0.00089 3.2 34.1
Carboxypeptidase X1 CPXM1 0.00137 36.1 31.6
ADAMTS12 ADAMTS12 0.00170 20.3 32.3
Adipocyte-enhanced binding protein 1 AEBP1 0.00170 2.2 24.6
Collagenase 3 MMP13 0.00170 26.0 27.1
ADAM9 ADAM9 0.00256 1.8 27.3
FACE-2/RCE1 FACE2 0.00256 0.80 29.6
X-Pro dipeptidase PEPD 0.00256 2.1 31.2
Leukotriene A4 hydrolase LTA4H 0.00313 0.51 26.7
NAALADASE like 2 NAALADL2 0.00313 3.8 31.0
Neprilysin MME 0.00313 9.8 30.9Available online http://arthritis-research.com/content/11/3/R96
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human Hutchinson – Gilford progeria and a concomitant
increase in autophagy [32]. One Zmpste null line displays
some growth plate phenotype [33]. Zmpste24 and the related
protease Rce1 are both altered in expression in OA cartilage,
although the increase in Zmpste24 is difficult to explain in
terms of these observations.
There are also many proteases involved in the removal of ubiq-
uitin (and ubiqutin-like) modifications from proteins, thereby
impacting upon protein degradation, intracellular localization
and epigenetic modification. These include the ubiquitin C-ter-
minal hydrolases, ubiquitin-specific proteases, OTU-domain-
containing proteases and SUMO (small ubiquitin-like modifier)
proteases, many of which are expressed in cartilage and regu-
lated during OA in the present study. This obviously has the
potential to impact upon many areas of cell function – includ-
ing, for example, transforming growth factor beta signalling,
where the action of Smurf2, an E3 ubiquitin ligase, may lead to
degradation of Smad proteins, reduced transforming growth
factor beta signalling and OA-like changes [34]. Sox9, the key
transcription factor in chondrogenesis, is also subject to ubiq-
uitination and proteosomal degradation, regulating transcrip-
tional activity [35]. Interestingly, the expression of ubiquitin
itself is significantly decreased in OA cartilage compared with
normal in our sample cohort (data not shown).
γ-Glutamyl hydrolase is another cysteine protease showing a
significantly increased expression in OA cartilage. This
enzyme is involved in folate metabolism, which has been
reported as necessary to chondrocytes for correct growth and
differentiation [36].
The metzincins (MMPs, ADAMs and ADAMTSs) have been
discussed above and previously [7], but the expression of sev-
eral other metalloproteases is altered in OA cartilage. Along
with ADAMTS2 and ADAMTS14 (collagen N-propeptidases),
both tolloid-like 1 and BMP1 (collagen C-propeptidases) are
also increased in expression in OA. The same is true for the
COL2A1 gene and indeed COL1A1 and COL1A2 genes in
our samples (data not shown), reflecting an increased colla-
gen synthesis previously described in OA cartilage [1].
Carboxypeptidase Z removes carboxyl-terminal basic amino
acids from proteins and has been shown to modulate Wnt sig-
nalling in the developing skeleton, with the cysteine-rich
domain acting as a binding site for Wnts. In the growth plate,
carboxypeptidase Z is co-expressed with Wnt4, although this
is not true in our articular cartilage samples (data not shown).
Overexpression of carboxypeptidase Z activates Wnt signal-
ling and promotes the terminal differentiation of growth plate
chondrocytes [37].
Four aminopeptidases or aminopeptidase-like enzymes are
amongst the metalloprotease genes most significantly
increased in expression in OA cartilage. Aminopeptidase N is
identical to CD13, a cell surface marker used to identify mes-
enchymal stem cells [38]. The function of any of these
enzymes in cartilage is unknown.
MMP3 (stromelysin 1) is one of the most highly expressed pro-
teases in cartilage and was significantly decreased in expres-
sion in OA in the current study and in our two previous studies
of gene expression in cartilage [7,11]. The function of MMP3
in cartilage homeostasis is not certain, although it is capable
of degrading aggrecan and also of activating procollagenases.
It is possible that MMP3 has a maintenance function in carti-
lage that is lost in end-stage OA.
ADAM8 ADAM8 0.00464 2.0 34.1
Aminoacylase ACY1 0.00464 1.6 33.2
O-Sialoglycoprotein endopeptide OSGEP 0.00464 1.8 29.7
ADAMTS7 ADAMTS7 0.00561 15.0 34.0
Dihydroorotase CAD 0.00561 1.4 28.1
ADAMTS6 ADAMTS6 0.00677 2.0 31.3
FACE-1/ZMPSTE24 FACE1 0.00677 1.8 30.9
Glutaminyl cyclase 2 QPCTL 0.00677 0.65 29.4
OMA1 OMA1 0.00813 0.50 27.6
Archaemetzincin-1 AMZ1 0.00974 0.58 31.4
Collagenase 1 MMP1 0.00974 0.24 30.8
Neurolysin NLN 0.00974 1.6 30.7
Fold change and median threshold cycle for all metalloprotease genes showing significant difference at P < 0.01 between osteoarthritis (OA) 
versus fracture to the neck of femur (NOF). P value from the Mann-Whitney U test. ADAM, a disintegrin and metalloproteinase domain; ADAMTS, 
a disintegrin and metalloproteinase domain with thrombospondin motifs; MMP, matrix metalloproteinase.
Table 5 (Continued)
Fold change and threshold cycle for metalloproteases showing significant difference between OA and NOFArthritis Research & Therapy    Vol 11 No 3    Swingler et al.
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Pappalysin-2 is also decreased in expression in OA cartilage.
This enzyme has been shown to degrade IGF binding protein-
5 and to some extent IGF binding protein-3 [39], and therefore
has the potential to control IGF availability in cartilage. Trans-
forming growth factor-beta-induced chondrocyte proliferation
was recently shown to be mediated by ADAM12-mediated
degradation of IGF binding protein-5 [40].
Htra1 is a serine protease that has previously been implicated
in cartilage destruction during OA [41]. Htra3 has not been
associated with OA, but in this study the gene is expressed at
a similar level in cartilage as Htra1 and is increased in expres-
sion in OA with comparable fold change and significance.
The expression of a number of proprotein convertases is
altered in OA cartilage compared with normal cartilage, with
the PCSK6 gene (PACE4) most highly regulated. Proprotein
convertases are responsible for the activation of a number of
proMMPs and proADAMTSs, with PACE4 recently identified
as the enzyme that activates aggrecanases in chondrocytes
[42].
Table 6
Fold change and threshold cycle for serine and threonine proteases significant between OA and NOF
Gene name Gene symbol P value Fold change OA/NOF Median threshold cycle
Complement component 2 C2 0.00005 11.7 29.6
Complement factor I CFI 0.00005 7.8 30.5
Heat shock 90 kDa protein 1 beta HSP90AB1 0.00005 0.54 25.4
HTRA3 HTRA3 0.00005 3.3 27.3
Lysosomal carboxypeptidase A CTSA 0.00005 2.3 25.8
Osteoblast serine protease HTRA1 0.00005 3.0 27.7
PACE4 proprotein convertase PCSK6 0.00005 7.5 30.8
Protein C-like PROCL 0.00006 9.3 30.6
Rhomboid 5 homolog 1 RHBDF1 0.00006 2.0 28.3
Rhomboid 5 homolog 2 RHBDF2 0.00008 0.40 27.9
Complement factor B CFB 0.00014 0.43 27.5
Seprase FAP 0.00017 4.0 28.0
Proprotein convertase 7 PCSK7 0.00022 1.8 28.6
Epoxide hydrolase EPHX1 0.00057 2.1 30.1
Presenilins-associated rhomboid like PARL 0.00071 0.69 26.8
Rhomboid domain containing 1 RHBDD1 0.00071 0.58 26.1
Glycosylasparaginase AGA 0.00111 1.9 29.9
Heat shock protein 90 kDa beta HSP90B1 0.00137 0.63 24.5
HTRA4 HTRA4 0.00137 3.6 32.1
Serine carboxypeptidase 1 SCPEP1 0.00209 1.9 26.3
Complement factor D DF 0.00313 3.8 31.0
Kallikrein hK4 KLK4 0.00382 10.3 34.4
Vitellogenic carboxypeptidase-L CPVL 0.00382 6.2 31.6
Proprotein convertase 1 PCSK1 0.00464 0.10 30.7
Reelin RELN 0.00464 5.6 30.0
Dipeptidyl-peptidase II DPP7 0.00813 1.6 26.1
Lysosomal Pro-X C-peptidase PRCP 0.00974 1.7 27.2
Proteasome catalytic subunit 1 PSMB6 0.00974 1.5 27.2
Fold change and median threshold cycle for all serine and threonine protease genes showing significant difference at P < 0.01 between 
osteoarthritis (OA) versus fracture to the neck of femur (NOF). P value from the Mann-Whitney U test.Available online http://arthritis-research.com/content/11/3/R96
Page 11 of 14
(page number not for citation purposes)
Four genes encoding complement factors are regulated in OA
cartilage compared with normal, with CFI, C2 and DF increas-
ing and CFB decreasing. In the complement pathway, C2 is
part of the classical pathway and CFB and DF are part of the
alternative pathway with CFI inhibiting C3b. CFI was also
recently described as increasing in expression in the lesion
site of an OA knee compared with macroscopically normal car-
tilage from the same knee [43]. Other relevant functions for
complement factors in OA have also been described, with
C1s recently identified as the protease in OA synovial fluid
responsible for cleavage of IGF binding protein-5 [44]. DF,
also known as adipsin, is used as a marker of adipose cells
and may be a readout for the differentiation status of the
chondrocytes in OA cartilage.
PROCL is also called 'regeneration-associated muscle pro-
tease' or RAMP, and is induced in regenerating skeletal mus-
cle in mice, as well as being lower in muscle cell lines derived
from Duchenne muscular dystrophy patients compared with a
normal cell line [45]. This protease may therefore have a role
in tissue regeneration, pertinent to cartilage in OA.
As already briefly discussed above, several members of the
rhomboid family of intramembrane proteases are expressed in
cartilage and altered in expression in OA. RHBDF1  has
recently been implicated in signalling from the epidermal
growth factor receptor [46] that is implicated in skeletal devel-
Figure 2
Ranking of genes Ranking of genes. (a) Rank scores by the Wilcoxon text. (b) Rank 
scores by the LogitBoost-NR algorithm.
Table 7
Ranking of genes using the LogitBoost-NR algorithm 
compared with the Wilcoxon test































For the top 30 genes ranked by LogitBoost-NR. For full gene names, 
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opment, as well as in autophagy [47]. PARL, a mitochondrial
rhomboid, is a regulator of apoptosis [48].
We have previously shown fibroblast activation protein alpha
to be elevated in OA cartilage and by inflammatory stimuli in
chondrocytes [49].
The gene encoded by Hsp90AB1 is a cytoplasmic heat shock
protein, whilst that encoded by Hsp90B1 is located in the
endoplasmic reticulum; both genes are highly expressed in
cartilage and significantly increased in OA. Heat shock pro-
teins act as molecular chaperones, and their induction may
indicate a level of cell stress. Heat shock protein 90 has also
been shown to mediate IGF-1 and IL-1β signalling in chondro-
cytes, and to contribute to the expression of the MMP13 gene
[50].
Conclusions
There are myriad possibilities for protease function in cartilage
metabolism, which may alter in OA, but a number of these
come to the fore in the results and discussion above: direct
proteolysis of extracellular matrix proteins or proteoglycans;
activation of other proteases; regulation of cell signalling (for
example, via IGF or IL-1); apoptosis and/or autophagy; and,
related to this, intracellular degradation of proteins.
The present study is the most complete quantitative analysis
of protease gene expression in cartilage to date. The data help
give direction to future research on the specific function(s) of
individual proteases or protease families in normal cartilage
and in OA.
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